Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

BACKGROUND: Immunotherapeutic regulation of the tumor microenvironment in prostate cancer patients is not understood. Most antibody immunotherapies have not succeeded in prostate cancer. We showed previously that high-risk PCa patients have a higher density of tumor infiltrating B-cells in prostatec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, Stephen T., Zhang, Jing, Burner, Danielle N., Liss, Michael, Pittman, Emily, Muldong, Michelle, Shabaik, Ahmed, Woo, Jason, Basler, Nicole, Cunha, Jonathan, Shalapour, Shabnam, Estrada, Monica V., Karin, Michael, Messer, Karen, Howell, Stephen, Kane, Christopher J., Jamieson, Christina A. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257145/
https://www.ncbi.nlm.nih.gov/pubmed/32466781
http://dx.doi.org/10.1186/s12967-020-02370-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257145/
https://www.ncbi.nlm.nih.gov/pubmed/32466781
http://dx.doi.org/10.1186/s12967-020-02370-4

Ejemplares similares